Central basic fibroblast growth factor inhibits gastric ulcer formation in rats.
We have recently reported that basic fibroblast growth factor (bFGF) acts in the brain to inhibit the secretion of gastric acid and pepsin, two major aggressive factors in the pathogenesis of gastric ulcer formation. In the present study, we determined whether or not bFGF has an anti-ulcer action via the central nervous system, using male Wistar rats. The intracisternal injection of bFGF dose-dependently (0.1-1.0 microgram(s)/rat) inhibited the severity of gastric ulcers induced by water-immersion restraint stress or central thyrotropin-releasing hormone. The same doses of peripherally injected bFGF failed to protect the gastric mucosa from these ulcerogenic procedures. These results suggest for the first time that bFGF has a mucosal protective effect through a mechanism involving the central nervous system. It is speculated that this anti-ulcer action of bFGF is, at least in part, dependent upon its gastric antisecretory effect.
Okumura
T
T
Department of Internal Medicine III, Asahikawa Medical College, Hokkaido, Japan.
Uehara
A
A
Kitamori
S
S
Takasugi
Y
Y
Namiki
M
M
D000818:Animals; D004334:Drug Administration Schedule; D016222:Fibroblast Growth Factor 2 / Q000008:administration & dosage / Q000494:pharmacology*; D005753:Gastric Mucosa / Q000187:drug effects / Q000378:metabolism; D008297:Male; D051381:Rats; D011919:Rats, Inbred Strains; D011994:Recombinant Proteins / Q000008:administration & dosage; D013276:Stomach Ulcer / Q000139:chemically induced / Q000209:etiology / Q000517:prevention & control*; D013312:Stress, Physiological / Q000150:complications; D013973:Thyrotropin-Releasing Hormone / Q000633:toxicity
D011994:Recombinant Proteins; D016222:Fibroblast Growth Factor 2; D013973:Thyrotropin-Releasing Hormone